scholarly journals Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry

2011 ◽  
Vol 52 (10) ◽  
pp. 1929-1935 ◽  
Author(s):  
Anna Abrahamsson ◽  
Nina Dahle ◽  
Mats Jerkeman
Keyword(s):  
Overall Survival ◽  
Mantle Cell Lymphoma ◽  
Marked Improvement ◽  
Cell Lymphoma ◽  
Population Based ◽  
Population Based Study ◽  
Mantle Cell

Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma

Blood ◽  
2012 ◽  
Vol 119 (18) ◽  
pp. 4215-4223 ◽  
Author(s):  
Lina Nygren ◽  
Stefanie Baumgartner Wennerholm ◽  
Monika Klimkowska ◽  
Birger Christensson ◽  
Eva Kimby ◽  
...  
Keyword(s):  
Overall Survival ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Eastern Cooperative Oncology Group ◽  
Population Based ◽  
Prognostic Role ◽  
P53 Expression ◽  
Mantle Cell ◽  
Indolent Disease

Abstract The prognostic role of the transcription factor SOX11 in mantle cell lymphoma (MCL) is controversial. We investigated prognostic markers in a population-based cohort of 186 MCL cases. Seventeen patients (9%) did not require any therapy within the first 2 years after diagnosis and were retrospectively defined as having an indolent disease. As expected, indolent MCL had less frequent B symptoms and extensive nodal involvement and 88% of these cases expressed SOX11. In our cohort 13 cases (7.5%) lacked nuclear SOX11 at diagnosis. SOX11− MCL had a higher frequency of lymphocytosis, elevated level of lactate dehydrogenase (LDH), and p53 positivity. The overall survival in the whole cohort, excluding 37 patients receiving autologous stem cell transplantation, was 3.1 year and in patients with indolent or nonindolent disease, 5.9 and 2.8 years, respectively (P = .004). SOX11− cases had a shorter overall survival, compared with SOX11+ cases, 1.5 and 3.2 years, respectively (P = .014). In multivariate analysis of overall survival, age > 65 (P = .001), Eastern Cooperative Oncology Group score ≥ 2 (P = .022), elevated LDH level (P = .001), and p53 expression (P = .001) remained significant, and SOX11 lost significance. We conclude that most indolent MCLs are SOX11+ and that SOX11 cannot be used for predicting an indolent disease course.

Mantle-cell lymphoma: a population-based clinical study.

1996 ◽  
Vol 14 (4) ◽  
pp. 1269-1274 ◽  
Author(s):  
G A Velders ◽  
J C Kluin-Nelemans ◽  
C J De Boer ◽  
J Hermans ◽  
E M Noordijk ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cyclin D1 ◽  
Mantle Cell Lymphoma ◽  
Survival Time ◽  
Cell Lymphoma ◽  
Population Based ◽  
Response To Therapy ◽  
Comprehensive Cancer Center ◽  
Overall Survival Time ◽  
Mantle Cell

PURPOSE From a population-based non-Hodgkin's lymphoma (NHL) registry, 41 patients with mantle cell lymphoma (MCL) -- a recently defined distinct B-cell NHL -- were selected and compared with patients with low- or intermediate-grade NHL from the same registry. PATIENTS AND METHODS The incidence and behavior of MCL in the area of the Comprehensive Cancer Center West (CCCW) from 1981 to 1989 were analyzed. Age, performance, tumor bulk, extranodal localization, stage, response to therapy, and survival were registered. Expression of cyclin D1 protein and Ki-67 were measured in 29 patients. RESULTS MCL made up 3.7% of NHLs. The median age was 68 years, and the male-to-female ratio was 1.6:1. Seventy-eight percent presented with stage IV, with the majority having bone marrow involvement. The complete response (CR) rate was 32% (13 of 41), with a median duration of 25 months. The median overall survival time was 31.5 months. The International Prognostic Index identified five patients with a low-risk score and a median survival time of 93+ months. In 23 of 29 patients, cyclin D1 overexpression was present, without any relation to overall or disease-free survival. In contrast, a proliferative index less than 10% was significantly related to a better overall survival time (50 v 24 months). CONCLUSION MCL is a disease of the elderly, who present with widespread disease and with a poor response to therapy. Although it harbors features of an indolent NHL, it behaves clinically as an aggressive NHL with a short overall survival time.

Mantle cell lymphoma epidemiology: a population-based study in France

2014 ◽  
Vol 93 (8) ◽  
pp. 1327-1333 ◽  
Author(s):  
Christophe Leux ◽  
Marc Maynadié ◽  
Xavier Troussard ◽  
Quentin Cabrera ◽  
Aurélie Herry ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Population Based ◽  
Population Based Study ◽  
Mantle Cell

A Danish population-based analysis of 105 mantle cell lymphoma patients

2002 ◽  
Vol 38 (3) ◽  
pp. 401-408 ◽  
Author(s):  
N.S Andersen ◽  
M.K Jensen ◽  
P de Nully Brown ◽  
C.H Geisler
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Population Based ◽  
Danish Population ◽  
Mantle Cell

Limited stage mantle cell lymphoma: Results of overall survival based on treatment modality using SEER database.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e19566-e19566
Author(s):  
Apoorva Jayarangaiah ◽  
Shuai Wang ◽  
Tarek N. Elrafei ◽  
Lewis Steinberg ◽  
Abhishek Kumar
Keyword(s):  
Overall Survival ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Stage I ◽  
Close Monitoring ◽  
Seer Database ◽  
Limited Stage ◽  
Number Of Patients ◽  
Significant Difference ◽  
Mantle Cell

e19566 Background: Limited stage mantle cell lymphoma (MCL) (stage I-II) is rare and occurs in 5-15% of patients. The ideal treatment approach among radiation (RT), chemotherapy (CT), chemoradiotherapy (CRT) or close monitoring (NT) has not been defined. Methods: A retrospective analysis of SEER database (1975 to 2018) was conducted for patients with stage I-II MCL to compare overall survival (OS) among the various treatment modalities in patients >18 years. We excluded patients lacking information on demographic characteristics and survival. Patients were analyzed in 4 groups; RT only, CT only, CRT and no treatment groups. ANOVA test and Chi-square test were used to evaluate parametric and non-parametric variables between groups, respectively. Cancer specific survival (CSS) and OS were assessed by Kaplan-Meier. SPSS 26.0 was used for data analysis. Results: There were in total 2266 patients with limited stage MCL. Median age was 71 years (61-78.25) and predominantly male (65.7%). Stage I MCL was noted in 55.6% and stage II in 44.4% of the patients. The number of patients in each group; RT only, CT only, CRT and NT along with the OS are presented in Table. CSS among these four groups showed no statistically significant differences (p <0.26). OS showed that CT only group has worse survival compared to RT only and CRT groups (p <0.001). CRT has no significant difference in survival compared to RT only (p<0.001). NT was associated with poorest survival rates (p<0.001). Conclusions: In limited stage MCL, RT only and CRT resulted in superior OS compared to CT only. Results suggest a role for incorporation of RT in treatment regimens. One limitation of the study is that the SEER database lacks the ability to distinguish between no receipt of therapy versus lack of availability of data.[Table: see text]

scholarly journals Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series

Healthcare ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 155
Author(s):  
Joaquim Carreras ◽  
Naoya Nakamura ◽  
Rifat Hamoudi
Keyword(s):  
Artificial Intelligence ◽  
Overall Survival ◽  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
High Accuracy ◽  
Gene Set Enrichment Analysis ◽  
Intelligence Analysis ◽  
Mantle Cell ◽  
Pan Cancer

Mantle cell lymphoma (MCL) is a subtype of mature B-cell non-Hodgkin lymphoma characterized by a poor prognosis. First, we analyzed a series of 123 cases (GSE93291). An algorithm using multilayer perceptron artificial neural network, radial basis function, gene set enrichment analysis (GSEA), and conventional statistics, correlated 20,862 genes with 28 MCL prognostic genes for dimensionality reduction, to predict the patients’ overall survival and highlight new markers. As a result, 58 genes predicted survival with high accuracy (area under the curve = 0.9). Further reduction identified 10 genes: KIF18A, YBX3, PEMT, GCNA, and POGLUT3 that associated with a poor survival; and SELENOP, AMOTL2, IGFBP7, KCTD12, and ADGRG2 with a favorable survival. Correlation with the proliferation index (Ki67) was also made. Interestingly, these genes, which were related to cell cycle, apoptosis, and metabolism, also predicted the survival of diffuse large B-cell lymphoma (GSE10846, n = 414), and a pan-cancer series of The Cancer Genome Atlas (TCGA, n = 7289), which included the most relevant cancers (lung, breast, colorectal, prostate, stomach, liver, etcetera). Secondly, survival was predicted using 10 oncology panels (transcriptome, cancer progression and pathways, metabolic pathways, immuno-oncology, and host response), and TYMS was highlighted. Finally, using machine learning, C5 tree and Bayesian network had the highest accuracy for prediction and correlation with the LLMPP MCL35 proliferation assay and RGS1 was made. In conclusion, artificial intelligence analysis predicted the overall survival of MCL with high accuracy, and highlighted genes that predicted the survival of a large pan-cancer series.

Sign in / Sign up

Export Citation Format

Share Document